01—Abstract
Summary
Summary of the 10-K filed February 23, 2021. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported total revenues of $267.6 milliona for 2020, up from $196.0 million in 2019, and net income of $129.1 million (basic EPS $0.95), compared with a net loss of $72.2 million in 2019.
The improvement was driven mainly by $123.0 millionb of revenues under collaborative agreements, including $69.5 million of event-based development milestones, and by royalty revenue of $88.6 million, up from $69.9 million, mainly from sales of DARZALEX FASPRO by Janssen. Product sales, net declined to $56.0 million from $66.1 million, primarily because of a one-off large partner order for bulk rHuPH20 in 2019. Research and development expense fell to $34.2 million from $140.8 million as the company halted PEGPH20 development after the HALO-301 trial failed its primary endpoint and refocused on its ENHANZE platform and Hylenex.
The balance sheet carries a significant near-term obligation. The 1.25% Convertible Senior Notes due 2024 ($460.0 millionc principal, $397.2 million net carrying amount) are classified as a current liability because the conditional conversion feature was triggered as of December 31, 2020. Cash, cash equivalents and marketable securities totaled $368.0 million, and working capital was $133.4 million.
The company stated it believes current cash will fund operations for at least the next twelve months, and in January 2021 it notified noteholders it will settle the note principal in cash. The company also reported an accumulated deficit of $474.6 milliond and repurchased 6.5 million shares for $150.0 million in 2020 under a $550.0 million three-year capital return program.
The filing describes Halozyme as a biopharma technology platform company that licenses its rHuPH20-based ENHANZE drug delivery technology to ten collaborations, with five marketed partnered products and Hylenex recombinant as its one proprietary marketed product. Dependence on collaborators, third-party contract manufacturers and regulatory approvals remain key risks identified in the filing.
02—Key points
Key Highlights
- Total revenues rose to $267.6 million in 2020 from $196.0 million in 2019, and the company reported net income of $129.1 million versus a net loss of $72.2 million a year earlier.
- Revenues under collaborative agreements reached $123.0 million, including $69.5 million of event-based development milestones and regulatory milestone and other fees, with new collaborations with Janssen, Horizon, Roche, argenx and BMS contributing license revenue.
- Royalty revenue increased to $88.6 million from $69.9 million, mainly driven by DARZALEX FASPRO sales by Janssen following its U.S. launch in the second quarter of 2020.
- Research and development expense decreased to $34.2 million from $140.8 million after PEGPH20 development was halted following the failed HALO-301 Phase 3 trial.
- The $460.0 million 1.25% Convertible Senior Notes due 2024 are classified as a current liability at December 31, 2020 because the conditional conversion feature was triggered; the company notified holders in January 2021 that it will settle principal in cash.
- Cash, cash equivalents and marketable securities totaled $368.0 million at December 31, 2020, and management believes this is sufficient to fund operations for at least the next twelve months.
- The company repurchased 6.5 million shares for $150.0 million in 2020 under a $550.0 million three-year capital return program, with $199.9 million remaining available under the program at December 31, 2020.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Halozyme Therapeutics kept $0.48.
- Revenue$267.6M100.0%
- Cost of revenue−$43.4M16.2%
- Gross profit$224.2M83.8%
- Operating costs−$80.0M29.9%
- Operating income$144.3M53.9%
- Interest, other & tax−$15.2M5.7%
- Net income$129.1M48.2%
Where FY2020 revenue went
$267.6M- Net income: $129.1M, 48% of revenue
- SG&A: $45.7M, 17% of revenue
- Cost of revenue: $43.4M, 16% of revenue
- R&D: $34.2M, 13% of revenue
- Interest, other & tax: $15.2M, 5.7% of revenue
Kept 48% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 23, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $267.59M$195.99M | +36.5% |
| Cost of Revenue | $43.37M$45.55M | −4.8% |
| Gross Profit | $224.23M$150.45M | +49.0% |
| R&D Expenses | $34.24M$140.80M | −75.7% |
| SG&A Expenses | $45.74M$77.25M | −40.8% |
| Operating Expenses | $123.34M$263.60M | −53.2% |
| Operating Income | $144.25M-$67.61M | +313.4% |
| Interest Expense | $20.38M$11.63M | +75.3% |
| Net Income | $129.09M-$72.24M | +278.7% |
| EPS (Basic) | $0.95$-0.50 | +290.0% |
| EPS (Diluted) | $0.91$-0.50 | +282.0% |
| Shares Outstanding (Basic) | 136.21M144.33M | −5.6% |
| Shares Outstanding (Diluted) | 141.46M144.33M | −2.0% |
05—Questions
Frequently Asked Questions
Why did Halozyme swing to net income in 2020?
Net income of $129.1 million in 2020 compared with a net loss of $72.2 million in 2019. Operating income was $144.3 million versus an operating loss of $67.6 million, reflecting higher collaboration revenue ($123.0 million versus $60.0 million), higher royalties ($88.6 million versus $69.9 million), and lower research and development ($34.2 million versus $140.8 million) and SG&A ($45.7 million versus $77.3 million) expenses. The filing also notes a $67.3 million tax benefit line item from a worthless stock deduction of an international subsidiary, which reduced income tax expense to $0.2 million.
What is the risk associated with the convertible notes?
The $460.0 million principal of 1.25% Convertible Senior Notes due December 1, 2024 is classified as a current liability because the conditional conversion feature was triggered as of December 31, 2020, which reduces working capital. Holders may require repurchase for cash upon certain circumstances. The company stated it believes early conversion is remote and that it can generate sufficient cash flow or raise capital to satisfy any conversion, and it notified holders in January 2021 that principal will be settled in cash.
What drives Halozyme's revenue?
Revenue comes from three sources: royalties on partner product sales ($88.6 million in 2020), product sales of bulk rHuPH20, ENHANZE drug product and Hylenex ($56.0 million in 2020), and revenues under collaborative agreements ($123.0 million in 2020) that include upfront license fees, milestones and research services. The filing notes that collaboration revenue is variable and depends on collaborators achieving clinical and regulatory milestones, and it identifies Janssen's DARZALEX FASPRO as a key driver of recent royalty growth.
What are the main risks highlighted in the filing?
The filing identifies dependence on collaboration partners to develop and commercialize products, the need for regulatory approvals of partner products, reliance on third-party contract manufacturers for bulk rHuPH20 (Avid Bioservices and Catalent) and fill and finish (Patheon), potential competition for Hylenex from Vitrase and Amphadase, pricing and reimbursement pressures, and the impact of COVID-19 on operations and partner timelines. It also cites patent expiration risk and the possibility of needing to raise additional capital.
06—Continue